CN110785172A - Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途 - Google Patents

Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途 Download PDF

Info

Publication number
CN110785172A
CN110785172A CN201880042082.2A CN201880042082A CN110785172A CN 110785172 A CN110785172 A CN 110785172A CN 201880042082 A CN201880042082 A CN 201880042082A CN 110785172 A CN110785172 A CN 110785172A
Authority
CN
China
Prior art keywords
trypsin
animal
human
compound
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880042082.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·法西
M·勒维蒂
T·普拉赛
D·艾布拉姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of CN110785172A publication Critical patent/CN110785172A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880042082.2A 2017-07-21 2018-07-13 Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途 Pending CN110785172A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762535376P 2017-07-21 2017-07-21
US62/535,376 2017-07-21
US201762574449P 2017-10-19 2017-10-19
US62/574,449 2017-10-19
US201762589734P 2017-11-22 2017-11-22
US62/589,734 2017-11-22
PCT/IB2018/000881 WO2019016595A1 (en) 2017-07-21 2018-07-13 USE OF WX-UK1 AND ITS PRODRANT WX-671 FOR THE TREATMENT OF NON-CANCER MEDICAL DISEASES

Publications (1)

Publication Number Publication Date
CN110785172A true CN110785172A (zh) 2020-02-11

Family

ID=65014605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880042082.2A Pending CN110785172A (zh) 2017-07-21 2018-07-13 Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途

Country Status (14)

Country Link
US (1) US20190022088A1 (https=)
EP (1) EP3654979A4 (https=)
JP (1) JP2020527582A (https=)
KR (1) KR20200031567A (https=)
CN (1) CN110785172A (https=)
AU (1) AU2018303799A1 (https=)
CA (1) CA3070037A1 (https=)
CL (1) CL2020000096A1 (https=)
IL (1) IL271878A (https=)
PH (1) PH12019502817A1 (https=)
RU (1) RU2020107706A (https=)
SG (1) SG11201912043QA (https=)
WO (1) WO2019016595A1 (https=)
ZA (1) ZA201908545B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494392A (zh) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的组合物及其应用
CN111494602A (zh) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 一种治疗急性胰腺炎的组合物及其用途
CN113559100A (zh) * 2021-08-30 2021-10-29 广州领晟医疗科技有限公司 一种治疗肺损伤的组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534498A (en) * 1992-01-30 1996-07-09 Corvas International, Inc. Trypsin inhibitors
US20040138233A1 (en) * 1998-07-20 2004-07-15 Wilex Ag Novel urokinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
EP3309556B1 (en) * 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534498A (en) * 1992-01-30 1996-07-09 Corvas International, Inc. Trypsin inhibitors
US20040138233A1 (en) * 1998-07-20 2004-07-15 Wilex Ag Novel urokinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLAIRE ROLLAND-FOURCADE 等: "Epithelial expression and function of trypsin-3 in irritable bowel syndrome", 《NEUROGASTROENTEROLOGY》 *
OLDENBERG EMIL ET 等: "New potential therapeutic applications of WX-UK1 as a specific and potent inhibitor of human trypsin-2 and human trypsin-3", 《HTTP://MCT.AACRJOURNALS.ORG/CONTENT/17/1_SUPPLEMENT/B055》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494392A (zh) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的组合物及其应用
CN111494602A (zh) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 一种治疗急性胰腺炎的组合物及其用途
CN111494602B (zh) * 2020-04-14 2023-06-02 广州领晟医疗科技有限公司 一种治疗急性胰腺炎的组合物及其用途
CN113559100A (zh) * 2021-08-30 2021-10-29 广州领晟医疗科技有限公司 一种治疗肺损伤的组合物及其应用
CN113559100B (zh) * 2021-08-30 2023-01-17 广州领晟医疗科技有限公司 一种治疗肺损伤的组合物及其应用

Also Published As

Publication number Publication date
SG11201912043QA (en) 2020-02-27
EP3654979A4 (en) 2021-04-14
RU2020107706A (ru) 2021-08-23
JP2020527582A (ja) 2020-09-10
CL2020000096A1 (es) 2020-08-28
PH12019502817A1 (en) 2020-09-14
CA3070037A1 (en) 2019-01-24
RU2020107706A3 (https=) 2021-10-15
US20190022088A1 (en) 2019-01-24
AU2018303799A1 (en) 2019-12-19
IL271878A (en) 2020-02-27
ZA201908545B (en) 2021-02-24
WO2019016595A1 (en) 2019-01-24
EP3654979A1 (en) 2020-05-27
KR20200031567A (ko) 2020-03-24

Similar Documents

Publication Publication Date Title
TW200924739A (en) Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
JP7301741B2 (ja) 補体活性のモジュレータ
US11180560B2 (en) Compositions and methods to treat solid tumors
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
US20210215714A1 (en) Complement alternative pathway-associated nephropathy biomarkers
CN110785172A (zh) Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途
CN110831668A (zh) 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗
JP2017528448A (ja) プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法
JP2023540393A (ja) カテプシンｃ阻害剤により転移を治療するための方法
WO2025015149A2 (en) Methods of treating cancer
Nimishakavi et al. Divergent inhibitor susceptibility among airway lumen-accessible tryptic proteases
CN101669934B (zh) 芒果苷元在制备治疗肥胖症的药物中的应用
US20240327364A1 (en) Therapeutic targeting of gpr68 to induce ferroptosis
TWI804010B (zh) 作為血液學毒性生物標記之gdf-15
ES2919898B2 (es) Nuevo tratamiento del cáncer colorrectal
CN114668843B (zh) 一种纳米自组装糖肽biva-pk及其在缺血再灌注损伤导致的肾脏纤维化中的应用
US20230045142A1 (en) Small molecule rpn13 inhibitors with antitumor properties
Xu et al. Macrophage TRIM21 Inhibition Ameliorates Murine Acute Pancreatitis via PHB2‐Mediated Mitochondrial Stabilization
JP5054529B2 (ja) フェニルアラニン誘導体の安定な投与形
US10208028B1 (en) Methods of treating cancer
Breault Preclinical Investigation of Mitochondrial Fission Inhibitors in Pulmonary Arterial Hypertension and Non-Small Cell Lung Cancer
US20120094923A1 (en) Methods and materials for assessing prostate cancer recurrence and reducing mesotrypsin activity
HK40106737A (zh) 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂
US20120277236A1 (en) Method for inhibiting mmp-9 dimerization
TW201350850A (zh) 抗癌劑之篩檢方法，以及以增大顆粒酶 ｍ之活性之物質做為有效成分的誘導細胞死亡之抗癌劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200211